Faculty Collaboration Database

Phase II trial of suramin in patients with metastatic renal cell carcinoma. Invest New Drugs 1999;17(2):183-6

Date

01/19/2000

Pubmed ID

10638490

DOI

10.1023/a:1006331518952

Scopus ID

2-s2.0-0032785794 (requires institutional sign-in at Scopus site)   27 Citations

Abstract

This study was conducted to assess the efficacy and toxicity of suramin administered using a fixed dose schedule in patients with advanced renal cell carcinoma. Fourteen eligible patients with advanced renal cell carcinoma were enrolled and treated on a fixed dose schedule of suramin administered over 12 weeks. Suramin was administered by intravenous infusions over 1 hour. None of the 13 evaluable patients demonstrated an objective response. Only 3 patients completed the 12-week therapy course, with the majority developing progressive disease on therapy. The fixed dosage schedule was well tolerated with minimal to moderate toxicity. Suramin in this fixed dose schedule is well tolerated but has no activity in advanced renal cell carcinoma.

Author List

Dreicer R, Smith DC, Williams RD, See WA

MESH terms used to index this publication - Major topics in bold

Adult
Aged
Carcinoma, Renal Cell
Drug Administration Schedule
Female
Humans
Infusions, Intravenous
Kidney Neoplasms
Male
Middle Aged
Neoplasm Metastasis
Suramin
Treatment Outcome